Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease

Journal of Clinical Investigation

Volumn 120, Issue 2, 2010, Pages 627-635

  Rosch, Jason W ^a   Boyd, Angela R ^b   Hinojosa, Ernesto ^b   Pestina, Tamara ^a   Hu, Yunming ^a   Persons, Derek A ^a   Orihuela, Carlos J ^b   Tuomanen, Elaine I ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOLYSIN; CYTOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PNEUMOLYSIN; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL VIRULENCE; CELL INVASION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOLYSIS; ENDOCYTOSIS; EPITHELIUM; FEMALE; GRAM POSITIVE BACTERIUM; HOST CELL; HYPOTHESIS; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; SICKLE CELL ANEMIA; SURVIVAL; TOXICITY;

ANEMIA, SICKLE CELL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL PROTEINS; CYTOTOXINS; DISEASE MODELS, ANIMAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PLATELET MEMBRANE GLYCOPROTEINS; PNEUMOCOCCAL INFECTIONS; RECEPTORS, G-PROTEIN-COUPLED; STREPTOLYSINS;

EID: 76649105064     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39843     Document Type: Article

References (46)

1. WHO. Sickle-cell disease and other haemoglobin disorders [fact sheet]. WHO Media Centre; August 2006. http://www.who.int/mediacentre/factsheets/fs308/ en/. Accessed December 3, 2009.
2. Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis. 1999;14:191-218.
3. Wardlaw T, Johansson EW, Hodge M. Pneumonia: The Forgotten Killer of Children. UNICEF/WHO; 2006. http://www.unicef.org/publications/index-35626. html. Accessed December 3, 2009.
4. Overturf G, Field R, Lam C, Lee S, Powars DR. Nasopharyngeal carriage of pneumococci in children with sickle cell disease. Infect Immun. 1980;28(3):1048-1050.
5. Orihuela CJ, et al. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest. 2009;119(6):1638-1646.
6. Radin JN, et al. beta-Arrestin 1 participates in platelet-activating factor receptor-mediated endocytosis of Streptococcus pneumoniae. Infect Immun. 2005;73(12):7827-7835.
7. Hinojosa E, Boyd AR, Oriheula CJ. Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J Infect Dis. 2009;200(4):546-554.
8. Belcher JD, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953-3959.
9. Miller ML, Gao G, Pestina T, Persons D, Tuomanen E. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis. 2007;195(4):581-584.
10. Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad STO, Conran N, Costa FF. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol. 2009;85(2):235-242.
11. Gatson MH, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314(25):1593-1599.
12. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis. 1996;174(5):986-993.
13. Collina R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomized placebo controlled trial. Lancet. 2002;360(9326):7-22.
14. Merx MW, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004;109(21):2560-2565.
15. Winkler F, Angele B, Pfister H, Koedel U. Simvastatin attenuates leukocyte recruitment in experimental bacterial meningitis. Int Immunopharmacol. 2009;9(3):371-374.
16. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007;7(5):358-368.
17. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729-734.
18. Almog Y, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110(7):880-885.
19. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1026-L1032.
20. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in commuity-acquired pneumonia. Am J Med. 2008;121(11):1002-1007.
21. Thomsen RW, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,000 patients. Arch Intern Med. 2008;168(19):2081-2087.
22. Paszty C, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278(5339):876-878.
23. Zeki AA, Franzi L, Last J, Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009;180(8):731-740.
24. Holtzclaw JD, Jack D, Aguayo SM, Eckman JR, Roman J, Hsu LL. Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice. Am J Respir Crit Care Med. 2004;169(6):687-695.
25. Brittain JE, Parise LV. Cytokines and plasma factors in sickle cell disease. Curr Opin Hematol. 2007;14(5):438-443.
26. Novack V, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trials. Intensive Care Med. 2009;35(7):1255-1260.
27. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995;377(6548):435-438.
28. Wolfrum S, Jensen KS, Liao JK. Endotheliumdependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23(5):729-736.
29. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007;28(2):88-98.
30. Kalyanasundaram A, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg. 2006;43(1):117-124.
31. Dichtl W, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(1):58-63.
32. Rijneveld AW, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis. 2004;189(4):711-716.
33. Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med. 2008;8(6):497-509.
34. Rosado CJ, et al. The MACPF/CDC family of poreforming toxins. Cell Microbiol. 2008;10(9):1765-1774.
35. Soltani CE, Hotze EM, Johnson AE, Tweten RK. Structural elements of the cholesterol-dependent cytolysins that are responsible for their cholesterol-sensitive membrane interactions. Proc Natl Acad Sci U S A. 2007;104(51):20226-20231.
36. Rosch JW, Sublett J, Gao G, Wang YD, Tuomanen EI. Calcium efflux is essential for bacterial survival in the eukaryotic host. Mol Microbiol. 2008;72(1):12-25.
37. Lacks S, Hotchkiss RD. A study of the genetic material determining enzyme in the pneumococcus. Biochim Biophys Acta. 1960;39:508-517.
38. Solovey A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3):840-846.
39. Kureishi Y, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004-1010.
40. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther. 2009;17(2):245-252.
41. Persons D, Hargrove W, Allay E, Hanawa H, Neinhuis A. The degree of phenotypic correction of murine beta thalassemia intermedia following lentiviral-mediated transfer of human gammaglobulin gene is influenced by chromosomal position effects and vector copy number. Blood. 2003;101(6):2175-2183.
42. Fillon S, et al. Platelet-activating factor receptor and innate immunity: uptake of gram-positive bacterial cell wall into host cells and cell-specific pathophysiology. J Immunol. 2006;177(9):6182-6191.
43. Orihuela CJ, Radin JN, Sublett JE, Gao G, Kaushal D, Tuomanen EI. Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun. 2004;72(10):5582-5596.
44. Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR. Acridine orange/ethidium bromide (AO/EB) staining to detect apoptosis [published online 2006]. Cold Spring Harb Protoc. doi:10.1101/pdb. prot4493.
45. Braun JS, Novak R, Gao G, Murray PJ, Shenep JL. Pneumolysin, a protein toxin of Streptococcus pnuemoniae, induces nitric oxide production from macrophages. Infect Immun. 1999;67(8):3750-3756.
46. Pinkney M, Beachy E, Kehoe M. The thiol-activated toxin streptolysin O does not require a thiol group for cytolytic activity. Infect Immun. 1989;57(8):2553-2558.